Dynavax (DVAX) Tops Q2 EPS by 64c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Dynavax Reports Second Quarter 2022 Financial Results
August 4, 2022 4:02 PM EDTQ2 2022 total revenue of $256.5 million, up 386% from $52.8 million for Q2 2021HEPLISAV-B® vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021CpG 1018® adjuvant net product revenue of $222.6 million, up 471% from $39.0 million for Q2 2021On track for second consecutive year of profitabilityConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., Aug. 4, 2022 /PRNewswire/ -- Dynavax Technologies... More
